IP Verse

Administration Of Gamma Hydroxybutyrate With Monocarboxylate Transporters - EP2961399

The patent EP2961399 was granted to Jazz Pharmaceuticals Ireland on Nov 15, 2017. The application was originally filed on Feb 28, 2014 under application number EP14709858A. The patent is currently recorded with a legal status of "Revoked".

EP2961399

JAZZ PHARMACEUTICALS IRELAND
Application Number
EP14709858A
Filing Date
Feb 28, 2014
Status
Revoked
Jul 10, 2020
Publication Date
Nov 15, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HEXALAug 14, 2018MAIWALDADMISSIBLE
TER MEER STEINMEISTER & PARTNER PATENTANWALTE MBBAug 14, 2018TER MEER STEINMEISTER & PARTNERADMISSIBLE
HOFFMANN EITLEJul 23, 2018HOFFMANN EITLEADMISSIBLE

Patent Citations (37) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS20080264709
DESCRIPTIONWO2009US61312
DESCRIPTIONWO2010US33572
DESCRIPTIONDD237309
DESCRIPTIONGB1522450
DESCRIPTIONGB922029
DESCRIPTIONGB980279
DESCRIPTIONUS2009137565
DESCRIPTIONUS2012076865
DESCRIPTIONUS3325361
DESCRIPTIONUS3385886
DESCRIPTIONUS4155929
DESCRIPTIONUS4393236
DESCRIPTIONUS5380937
DESCRIPTIONUS5758095
DESCRIPTIONUS5833599
DESCRIPTIONUS5845255
DESCRIPTIONUS6014631
DESCRIPTIONUS6067524
DESCRIPTIONUS6112182
DESCRIPTIONUS6317719
DESCRIPTIONUS6356873
DESCRIPTIONUS6472431
DESCRIPTIONUS6780889
DESCRIPTIONUS7072840
DESCRIPTIONUS7262219
DESCRIPTIONUS7668730
DESCRIPTIONUS7765106
DESCRIPTIONUS7765107
DESCRIPTIONUS7797171
DESCRIPTIONUS7851506
DESCRIPTIONUS7895059
DESCRIPTIONUS8263650
DESCRIPTIONUS8324275
OPPOSITIONUS2003125385
OPPOSITIONUS6780889
OPPOSITIONWO2014134380

Non-Patent Literature (NPL) Citations (43) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "Annex II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARIESOF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLETS PRESENTED BY THEEUROPEAN MEDICINES AGENCY", EMA-Valproate, (20110429), pages 108 - 113, XP055516985
OPPOSITION- Anonymous, "Annex I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES", (20110429), pages 1 - 107, XP055516973
OPPOSITION- Anonymous, "Annex I Summary of Product Characteristics - Xyrem", pages 1 - 31
OPPOSITION- Anonymous, "Gamma-hydroxybutyric acid (GHB), Critical Review Report", WHO Expert Committee on Drug Dependence Thirty-Fifth Meeting, Hammamet, Tunisia, (20120604), pages 1 - 57, XP055517236
OPPOSITION- Anonymous, "gamma-Hydroxybutyric acid, Wikipedia, the free encyclopedia", (20130225), XP055517227
OPPOSITION- Anonymous, "Highlights of Prescribing Information - Depakene®", (20130200), page 43pp, XP055517250
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION: Xyrem®", Jazz Pharmaceuticals, Inc,, (20121200), page 30pp, XP055517002
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION: Xyrem®", Jazz Pharmaceuticals, Inc., (20121200), page 30pp, XP055517002
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION: Xyrem®", Jazz Pharmaceuticals, Inc,, (20160900), page 31pp, XP055516873
OPPOSITION- Anonymous, "Lithium Carbonate Tablets USP", Roxane Laboratories, Inc., (20111000), page 5pp, XP055516882
OPPOSITION- Anonymous, "Xyrem (Sodium Oxybate) - Mania - Suspected Cause - Side Effect Reports", DrugLib.com, URL: http://www.druglib.com/reported-side-effects/xyrem/reaction_mania/
OPPOSITION- Anonymous, "Xyrem@ Titration Schedule", Jazz Pharmaceuticals, Inc,, (20080000), page 1
OPPOSITION- BOJARSKI J; WASZKIELEWICZ A, "Gamma-Hydroxybutyric Acid (GHB) and Its Chemical Mdoficiations: A Review of the GHBergic System", Pol J Pharmacol., (20040000), vol. 56, no. 1, pages 43 - 49, XP008091834
OPPOSITION- BOJARSKI J; WASZKIELEWICZ A, "y-Hydroxybutyric acid (GHB) and its chemical modifications: a review of the GHBergic system", Polish Journal of Pharmacology, (20040000), vol. 56, pages 43 - 49, XP008091834
OPPOSITION- CHRISTOPHER D. CASH, "Gammahydroxybutyrate: An Overview of the Pros and Cons for it Being a Neurotransmitter And/Or a Useful Therapeutic Agent", Neuroscience and Biobehavioral Reviews, (19940000), vol. 18, no. 2, pages 291 - 304, XP055517014
OPPOSITION- David E Fuller, Carl S., Hornfeldt, "From Club Drug to Orphan Drug: Sodium Oxybate (Xyrem) for the Treatment of Cataplexy", Pharmacotherapy, (20030901), vol. 23, pages 1205 - 1209, XP055123175
OPPOSITION- David E. Fuller, Carl S. Hornfeldt, "From Club Drug to Orphan Drug: Sodium Oxybate (Xyrem) for the Treatn1ent of Cataplexy", Pharmacotherapy, (20030000), vol. 23, no. 9, pages 1205 - 1209, XP055123175
OPPOSITION- ELLER, M. et al., "Evaluation of drug-drug interactions of sodium oxybate with divalproex: Results from a pharmacokinetic/pharmacodynamic study", Abstracts/ Sleep Medicine, vol. 14S, pages e302 - e303, XP055517276
OPPOSITION- "ENZYME: 1.1.1.19", KEGG, URL: https://www.genome.jp/dbget-bin/www_bget?ec:1.1.1.19
OPPOSITION- Francesco P. Busardo and Alan W. Jones, "GHB Pharmacology and Toxicology: Acute Intoxication, Concentrations in Blood and Urine in Forensic Cases and Treatment of the Withdrawal Syndrome", Current Neuropharmacology, (20150000), vol. 13, no. 1, pages 47 - 70, XP055516914
OPPOSITION- Francesco P Busardo, Jones Alan W, "GHB Pharmacology and Toxicology: Acute Intoxication, Concentrations in Blood and urine in Forensic Cases and Treatment of the Withdrawal Syndrome", Current Neuropharmacology, (20150000), vol. 13, pages 47 - 70, XP055516914
OPPOSITION- FULLER et al., "From Club Drug to Orphan Drug: Sodium Oxybate Xyrem for the Treatment of Cataplexy", Pharmacotherapy, (20030900), vol. 23, no. 9, pages 1205 - 1209, XP055123175
OPPOSITION- HECHLER, V. et al., "gamma-Hydroxybutyrate Conversion into GABA Induces Displacement of GABA B Binding that is Blocked by Valproate and Ethosuximide 1", J. Pharmacol. Exp. Therap., (19970130), vol. 281, no. 2, pages 753 - 760, XP055123267
OPPOSITION- Jeremy Peacock & Ruth M. Benca, "Narcolepsy: Clinical features, co-morbidities & treatment", Indian J Med Res., (20100200), vol. 131, pages 338 - 349, XP055516952
OPPOSITION- Mark I. Crosby, David A Bradshaw, Robert N Mclay, "Severe Mania Complicating Treatment of Narcolepsy with Cataplexy", J Clin Sleep Med., (20110000), vol. 7, no. 2, pages 214 - 216, XP055516891
OPPOSITION- M S Okun, Boothby L A, Bartfield R B, Doering P L, "GHB: An important pharmacologic and clinical update", Journal of pharmacy & pharmaceutical sciences, (20010501), vol. 4, no. 2, pages 167 - 175, XP055516909
OPPOSITION- Sanjeev V. Kothare, Joseph Kaleyias, "Pharmacotherapy of Narcolepsy: Focus on Sodium Oxybate", Clinical Medicine Insights: Therapeutics, (20100000), vol. 2, pages 37 - 52, XP055516920
OPPOSITION- Viviane Hechler; Ratomponirina Charline; Maitre Michel, "gamma-Hydroxybutyrate Conversion into GABA Induces Displacement of GABA B Binding that is Blocked by Valproate and Ethosuximide 1", J Pharmacol Exp Ther., (19970130), vol. 281, no. 2, pages 753 - 760, XP055123267
OPPOSITION- William Horsley, "Sodium oxybate (Xyrem®) in the management of narcolepsy with cataplexy", North East Treatment Advisory Group, (20091200), pages 1 - 17, XP055517217
OPPOSITION- KAUFMAN E E; NELSON T, "An overview of y-hydroxybutyrate catabolism: The role of the cytosolic NADP+-dependent oxidoreductase EC 1.1.1.19 and of a mitochondrial hydroxyacid-oxiacid transhydrogenase in the initial, rate-limiting step in this pathway", NEUROCHEMICAL RESEARCH, (19910000), vol. 16, no. 9, pages 965 - 974, XP008082252
OPPOSITION- Indranil Bhattacharya; Kathleen M K Boje, "Potential [gamma]-Hydroxybutyric acid (GHB) Drug Interactions Through Blood-Brain Barrier Transport Inhibition: A Pharmacokinetic Simulation-Based Evaluation", Journal of Pharmacokinetics and Pharmacodynamics,, (20061000), vol. 33, no. 5, pages 657 - 681, XP019401210
OPPOSITION- O.C. Snead, L.J. Bearden, V. Pegram, "Effect of acute and chronic anticonvulsant administration on endogenous γ-hydroxybutyrate in rat brain", Neuropharmacology, (19800000), vol. 19, no. 1, pages 47 - 52, XP055517010
OPPOSITION- Vayer P; Cash C D; Maitre M, "Is the anticonvulsant mechanism of valproate linked to its interaction with the cerebral gamma-hydroxybutyrate system?", Trends in Pharmacological Sci., (19880400), vol. 9, no. 4, pages 127 - 129, XP023855737
OPPOSITION- MAITRE M, "The gamma-Hydroxybutyrate signaling system in brain: organization and functional implications", Progress in Neurobiology, (19970200), vol. 51, no. 3, pages 337 - 361, XP000877100
OPPOSITION- MAITRE M, "THE GAMMA-HYDROXYBUTYRATE SIGNALLING SYSTEM IN BRAIN: ORGANIZATION AND FUNCTIONAL IMPLICATIONS", Progress in Neurobiology,, (19970200), vol. 51, no. 3, pages 337 - 361, XP000877100
OPPOSITION- Wolfgang Löscher, "Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action", Progress Neurobiology, (19990601), vol. 58, no. 1, pages 31 - 59, XP055517204
OPPOSITION- Shinka T; Ohfu M; Hirose S; Kuhara T, "Effect of valproic acid on the urinary metabolic profile of a patient with succinic semialdehyde dehydrogenase deficiency", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATI,, (20030715), vol. 792, no. 1, pages 99 - 106, XP004431819
OPPOSITION- BILLIARD M; ET AL, "EFNS guidelines on management of narcolepsy", EUROPEAN JOURNAL OF NEUROLOGY,, (20061000), vol. 13, no. 10, pages 1035 - 1048, XP002535077
OPPOSITION- M. Eli, F. Cattabeni, "Endogenous gamma-Hydroxybutyrate in Rat Brain Areas: Postmortem Changes and Effects of Drugs Interfering with gamma-Aminobutyric Acid Metabolism", JOURNAL OF NEUROCHEMISTRY, (19830800), vol. 41, no. 2, pages 524 - 530, XP055517246
OPPOSITION- BHATTACHARYA I; BOJE K M K, "GHB (GAMMA-HYDROXYBUTYRATE) CARRIER-MEDIATED TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (20041000), vol. 311, no. 1, pages 92 - 98, XP009049440
OPPOSITION- Chi-Tso Chiu, Zhifei Wang, Joshua G. Hunsberger, and De-Maw Chuang, "Therapeutic Potential of Mood Stabilizers Lithium and Valproic Acid: Beyond Bipolar Disorder", PHARMACOLOGICAL REVIEWS, (20130101), vol. 65, no. 1, pages 105 - 142, XP055516897
OPPOSITION- Daniel Pardi, Black Jed, "γ-Hydroxybutyrate/Sodium Oxybate Neurobiology, and Impact on Sleep and Wakefulness", CNS Drugs, (20060000), vol. 20, no. 12, pages 993 - 1018, XP055516866
OPPOSITION- Daniel Pardi, Jed Black, "γ-Hydroxybutyrate/Sodium Oxybate Neurobiology, and Impact on Sleep and Wakefulness", CNS Drugs, (20061201), vol. 20, no. 12, pages 993 - 1018, XP055516866

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents